#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA2114000	F	OSM: Inhibition of Plasmodium falciparum 3D7 growth. IC50 values determined from 21 point dose response curves. Avery Group Griffith.	Plasmodium falciparum 3D7	71		organism-based format	Open Source Malaria Screening
2.	ALA2114002	F	OSM: Inhibition of Plasmodium falciparum 3D7 growth using a SYBR green I fluorescence based assay. GSK Tres Cantos.	Plasmodium falciparum 3D7	27		organism-based format	Open Source Malaria Screening
3.	ALA2114004	T	OSM: HEK293 cytotoxicity assay. Duplicate point single experiment at 120 uM. Avery Group, Griffith.	Homo sapiens	17		cell-based format	Open Source Malaria Screening
4.	ALA2114005	A	OSM: Kinetic solubility pH 2 0.01 M HCl ug/mL.		8		assay format	Open Source Malaria Screening
5.	ALA2114006	A	OSM: Kinetic solubility pH 6.5 isotonic phosphate buffer.		8		assay format	Open Source Malaria Screening
6.	ALA2114007	A	OSM: Microsomal stability: 0.5 uM substrate, 0.4 mg/mL protein, NADPH cofactor). Analysed by LC/MS. In vitro CLint (uL/min/mg protein).	Homo sapiens	7		microsome format	Open Source Malaria Screening
7.	ALA2114008	A	OSM: Microsomal stability: 0.5 uM substrate, 0.4 mg/mL protein, NADPH cofactor. Analysed by LC/MS. Degradation half life (min).	Homo sapiens	7		microsome format	Open Source Malaria Screening
8.	ALA2114009	A	OSM: Microsomal stability: 0.5 uM substrate, 0.4 mg/mL protein, NADPH cofactor. Analysed by LC/MS. Degradation rate classification.	Homo sapiens	8		microsome format	Open Source Malaria Screening
9.	ALA2114010	F	OSM: hERG, IC50 uM (Essen Bioscience): IonWorks patch clamp electrophysiology. 8 point concentration-response curves were generated using 3-fold serial dilutions from the maximum final assay concentration of 33 uM.	Homo sapiens	2		assay format	Open Source Malaria Screening
10.	ALA2114011	F	OSM: Mice are infected intravenously with parasitized red blood cells on day 0 (2 x 107 parasitized erythrocytes per ml). Experimental mice are generally treated at 4, 24, 48, and 72 hours post-infection with an oral dose of the compound (50 mg/kg, 4-day test by Peters) and are compared to an infected control group for reduction in parasitaemia on day 4 (96 hours post-infection) as a percentage.	Mus musculus	3		organism-based format	Open Source Malaria Screening
11.	ALA2114012	F	OSM: CSIR assay 3D7: Compounds were tested for inhibition of Plasmodium falciparum growth using a SYBR green I fluorescence based assay.	Plasmodium falciparum 3D7	3		organism-based format	Open Source Malaria Screening
12.	ALA2114013	F	OSM: CSIR assay K1: Compounds were tested for inhibition of Plasmodium falciparum growth using a SYBR green I fluorescence based assay.	Plasmodium falciparum K1	3		organism-based format	Open Source Malaria Screening
13.	ALA2114020	F	OSM: Inhibition of Plasmodium falciparum K1 growth. IC50 values determined from 21 point dose response curves. Avery Group Griffith.	Plasmodium falciparum K1	9		organism-based format	Open Source Malaria Screening
14.	ALA1054500	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
15.	ALA1054501	F	GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
16.	ALA1054502	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
17.	ALA1054503	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
18.	ALA1054504	F	GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.	Homo sapiens	13,467		cell-based format	GSK Malaria Screening
19.	ALA1054505	F	GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested		13,467		assay format	GSK Malaria Screening
20.	ALA3436042	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening